as 07-26-2024 4:00pm EST
AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of Aeterna's lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products and being developed as potential nutraceuticals and/or pharmaceuticals.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | N/A |
Market Cap: | 21.1M | IPO Year: | 1996 |
Target Price: | $60.00 | AVG Volume (30 days): | 11.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -14.86 | EPS Growth: | N/A |
52 Week Low/High: | $3.96 - $12.36 | Next Earning Date: | 08-07-2024 |
Revenue: | $2,374,000 | Revenue Growth: | -62.02% |
Revenue Growth (this year): | -2.49% | Revenue Growth (next year): | N/A |
AEZS Breaking Stock News: Dive into AEZS Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
GlobeNewswire
a month ago
Newsfile
2 months ago
CNW Group
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "AEZS Aeterna Zentaris Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.